A study to see how a single increasing dose of the oral drug AD-700 affects the ability of a CT scan to detect activated brown fat in healthy people

2025-520584-41-00 Protocol IBT-002 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 10 Mar 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 2 sites · Protocol IBT-002

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 21
Countries 1
Sites 2

Metabolism dysfunction

Key facts

Sponsor
Adiposs S.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Trial duration
10 Mar 2026 → ongoing
Decision date (initial)
2025-05-05
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Metabolism dysfunction

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Adiposs S.A.

Sponsor organisation
Adiposs S.A.
Address
Route De La Galaise 34
City
Plan-Les-Ouates
Postcode
1228
Country
Switzerland

Scientific contact point

Organisation
Adiposs S.A.
Contact name
Nathalie Stransky von Heilkron

Public contact point

Organisation
Adiposs S.A.
Contact name
Nathalie Stransky von Heilkron

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Finland Ongoing, recruiting 21 2
Rest of world 0

Investigational sites

Finland

2 sites · Ongoing, recruiting
Clinical Research Services Turku CRST Oy
N/A, Joukahaisenkatu 2 B, 20520, Turku
CRST Helsinki Oy
N/A, Energiakatu 4, 00180, Helsinki

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Finland 2025-06-05 2025-06-05

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Temporary halts 1 · Art. 38 CTR

Temporary halt TH-96564

Halt date
2025-08-18
Member states concerned
Finland
Publication date
2025-09-04
Reason
Sponsor decision
Follow-up measures
Subjects' follow-up is pursued as per protocol. A protocol amendment will be filed.
Benefit-risk balance changed
No
Treatment stopped
Yes

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-02-14 Finland Acceptable with conditions
2025-04-29
2025-05-05
2 SUBSTANTIAL MODIFICATION SM-1 2025-11-18 Finland Acceptable
2026-02-13
2026-03-10
3 NON SUBSTANTIAL MODIFICATION NSM-2 2026-03-12 Finland Acceptable
2026-02-13
2026-03-12